Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Neuro-Oncology Practice

• Publication date

  2014-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/NOP/NPU021PMID 26034628PMCID PMC4369716
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High procedure volume is strongly associated with improved survival after lung cancer surgery.

  2013cited by this paper
• Hospital and surgeon volume in relation to survival after esophageal cancer surgery in a population-based study.

  2013cited by this paper
• Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

  2013cited by this paper
• Brain tumor epidemiology in Austria and the Austrian Brain Tumor Registry.

  2013cited by this paper
• Glioblastoma management in the temozolomide era: have we improved outcome?

  2013cited by this paper
• Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain.

  2013cited by this paper
• Adherence to Treatment Guidelines for Ovarian Cancer as a Measure of Quality Care

  2013cited by this paper
• Patterns of care and survival for glioblastoma patients in the Veterans population

  2012cited by this paper
• Glioblastoma survival in the United States before and during the temozolomide era

  2012cited by this paper
• Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006.

  2012cited by this paper
• Improved survival time trends for glioblastoma using the SEER 17 population-based registries

  2012cited by this paper
• Epidemiology of glial and non-glial brain tumours in Europe.

  2012cited by this paper
• Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide (TMZ) therapy for high-grade gliomas (HGG) in Colombia (RedLANO registry).

  2011cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.

  2006cited by this paper
• Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer

  2002cited by this paper
• The value of capture-recapture methods even for apparent exhaustive surveys. The need for adjustment for source of ascertainment intersection in attempted complete prevalence studies.

  1992cited by this paper

• Real-world analysis of treatment patterns and survival outcome of glioblastoma patients in a German single-center study: Can survival rates of randomized controlled trials be achieved?

  2025cites this paper
• Achievements of international rare cancers networks and consortia in the neuro-oncology field

  2024cites this paper
• What predicts survival in glioblastoma? A population-based study of changes in clinical management and outcome

  2023cites this paper
• European Cancer Organisation Essential Requirements for Quality Cancer Care: adult glioma.

  2023cites this paper
• The impact of short-course hypofractionated radiotherapy on multimodality treatment utilisation, compliance, and outcome in glioblastoma patients: a Danish patterns of care study

  2023cites this paper
• Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period.

  2022cites this paper
• Histologic Findings at Time of Repeat Resection Predicts Survival in Patients with Glioblastoma.

  2022cites this paper
• Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.

  2021cites this paper
• Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term Management of IDH1-Mutant Glioblastoma: An 80-Month Follow-Up Case Report

  2021cites this paper
• Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study

  2021cites this paper
• Cancer clinical trial vs real‐world outcomes for standard of care first‐line treatment in the advanced disease setting

  2021cites this paper
• Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study.

  2021cites this paper
• Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment

  2020cites this paper
• Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis

  2020influential citation
• Glioblastoma: prognostic factors and predictive response to radio- and chemotherapy.

  2020cites this paper
• Treatment of recurrent glioblastoma: state-of-the-art and future perspectives

  2020cites this paper
• Ongoing improvements in postoperative survival of glioblastoma in the temozolomide era: a population-based data linkage study.

  2019cites this paper
• Effect of health disparities on overall survival of patients with glioblastoma

  2019cites this paper
• Gliomas: survival differences between metropolitan and non-metropolitan counties.

  2019cites this paper
• Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch Quality Registry for Neuro Surgery

  2019cites this paper
• Recurrent glioblastomas: Should we operate a second and even a third time?

  2019cites this paper
• Association of patterns of care, prognostic factors, and use of radiotherapy–temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study

  2018cites this paper
• The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power.

  2018cites this paper
• Characteristics and survival outcomes associated with the lack of radiation in the treatment of glioblastoma

  2018cites this paper
• Evolutionary basis of a new approach for the treatment of malignant brain tumors: from mice to humans

  2018cites this paper
• Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

  2017cites this paper
• 3.0T Imaging of Brain Gliomas

  2017cites this paper
• Does Pretreatment Tumor Growth Hold Prognostic Information for Patients with Glioblastoma?

  2017cites this paper
• Correction to: Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study

  2017cites this paper
• Incidence of neuroepithelial primary brain tumors among adult population of Emilia-Romagna Region, Italy

  2017cites this paper
• Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts

  2017cites this paper
• Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems

  2016cites this paper
• Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study

  2016cites this paper
• Concluding Remarks and Perspectives for Future Research

  2016cites this paper
• Clinical prognostic factors in adults with astrocytoma: Historic cohort.

  2016cites this paper
• Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.

  2016cites this paper
• Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor

  2016cites this paper
• Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009

  2015cites this paper